CareDx Inc
CDNA
查看详细走势图
19.450USD
+0.260+1.35%
收盘 12/19, 16:00（美东）报价延迟15分钟
999.87M总市值
14.42市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+1.35%
5天
-5.40%
1月
+21.71%
6月
+2.21%
今年开始到现在
-9.15%
1年
-5.35%
查看详细走势图
TradingKey CareDx Inc股票评分
单位: USD 更新时间: 2025-12-19操作建议
CareDx Inc当前公司基本面数据相对非常健康，增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名6/404位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价23.00。中期看，股价处于上升通道。近一个月，市场表现较强，技术面和基本面综合得分较高，较强的走势得到基本面和技术面的印证。目前股价在压力位和支撑位之间，可以做区间波段操作。
CareDx Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
分析师目标
根据
9
位分析师
买入
评级
23.000
目标均价
+21.69%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
CareDx Inc亮点
亮点风险
CareDx, Inc. is a precision medicine solutions company. The Company is focused on the discovery, development, and commercialization of clinically differentiated healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey and is the provider of genomics-based information for transplant patients. Its commercially available post-transplant testing services consist of AlloSure Kidney, a donor-derived cell-free DNA, or dd-cfDNA, solution for kidney transplant patients, AlloMap Heart, a gene expression profiling solution for heart transplant patients, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Its lab product portfolio includes QTYPE, Olerup SSP and SBT, AlloSeq Tx, AlloSeq HCT, and AlloSeq cfDNA. It also offers a diverse portfolio of digital solutions to transplant centers.
业绩转盈
公司业绩转盈，最新年度盈利美元
估值高估
公司最新PE估值14.42，处于3年历史高位
机构加仓
最新机构持股52.64M股，环比增加0.08%
PRFDX持仓
明星投资者PRFDX持仓，最新持仓市值14.98K
CareDx Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
CareDx Inc简介
CareDx, Inc. is a precision medicine solutions company. The Company is focused on the discovery, development, and commercialization of clinically differentiated healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey and is the provider of genomics-based information for transplant patients. Its commercially available post-transplant testing services consist of AlloSure Kidney, a donor-derived cell-free DNA, or dd-cfDNA, solution for kidney transplant patients, AlloMap Heart, a gene expression profiling solution for heart transplant patients, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Its lab product portfolio includes QTYPE, Olerup SSP and SBT, AlloSeq Tx, AlloSeq HCT, and AlloSeq cfDNA. It also offers a diverse portfolio of digital solutions to transplant centers.
公司代码CDNA
公司CareDx Inc
CEOHanna (John W)
网址https://www.caredx.com/
常见问题
CareDx Inc(CDNA)的当前股价是多少？
CareDx Inc(CDNA)的当前股价是 19.450。
CareDx Inc的股票代码是什么？
CareDx Inc的股票代码是CDNA。
CareDx Inc股票的52周最高点是多少？
CareDx Inc股票的52周最高点是25.950。
CareDx Inc股票的52周最低点是多少？
CareDx Inc股票的52周最低点是10.960。
CareDx Inc的市值是多少？
CareDx Inc的市值是999.87M。
CareDx Inc的净利润是多少？
CareDx Inc的净利润为52.55M。
现在CareDx Inc(CDNA)的股票是买入、持有还是卖出？
根据分析师评级，CareDx Inc(CDNA)的总体评级为买入，目标价格为23.000。
CareDx Inc(CDNA)股票的每股收益（EPS TTM）是多少
CareDx Inc(CDNA)股票的每股收益（EPS TTM）是1.349。
相关品种
